DAWN - Day One Biopharma draws bullish calls as quiet period ends
naphtalina/iStock via Getty Images Day One Biopharmaceuticals ([[DAWN]] +1.8%) has lost ~16.0% in value since its public debut in late May. Today as its IPO quiet period draws to a close, the clinical-stage biopharma company has attracted a range of bullish recommendations from Wall Street. The analysts from J.P. Morgan, Piper Sandler, Cowen, and Wedbush Securities have all initiated the coverage of the stock with buy-equivalent ratings. The price targets range from $38.00 to $30.00 per share with an average of $34.33 indicating a premium of ~63.5% to the previous close. Meanwhile, with a neutral rating on the stock, Seeking Alpha contributor Donovan Jones argued that Day One was “pursuing rather small markets,” and its IPO was “highly-priced.” The shares have received another boost today after the company announced that the European Commission granted it the orphan designation for its lead candidate DAY101 in the treatment of glioma.
For further details see:
Day One Biopharma draws bullish calls as quiet period ends